This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Bullish on Top Technology Stocks: Ceragon Networks (CRNT), Manhattan Associates (MANH)

Tipranks - Tipranks - Thu May 21, 5:32AM CDT

There’s a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Ceragon Networks (CRNT) and Manhattan Associates (MANH) with bullish sentiments.

Meet Samuel – Your Personal Investing Prophet

Ceragon Networks (CRNT)

In a report released today, Ryan Koontz from Needham maintained a Buy rating on Ceragon Networks, with a price target of $3.00. The company’s shares closed last Tuesday at $2.53, close to its 52-week low of $2.33.

According to TipRanks.com, Koontz is a top 100 analyst with an average return of 41.2% and a 53.8% success rate. Koontz covers the Technology sector, focusing on stocks such as Applied Optoelectronics, Lumentum Holdings, and Extreme Networks. ;'>

Currently, the analyst consensus on Ceragon Networks is a Strong Buy with an average price target of $3.67, which is a 45.1% upside from current levels. In a report released yesterday, TipRanks – PerPlexity also upgraded the stock to Buy with a $3.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Manhattan Associates (MANH)

William Blair analyst Dylan Becker maintained a Buy rating on Manhattan Associates today. The company’s shares closed last Tuesday at $135.42.

According to TipRanks.com, Becker is a 1-star analyst with an average return of -1.8% and a 40.4% success rate. Becker covers the Technology sector, focusing on stocks such as CCC Intelligent Solutions Holdings, Clearwater Analytics Holdings, and The Descartes Systems Group. ;'>

Manhattan Associates has an analyst consensus of Strong Buy, with a price target consensus of $198.14, which is a 41.0% upside from current levels. In a report issued on May 14, TipRanks – OpenAI also upgraded the stock to Buy with a $141.00 price target.

Read More on CRNT:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).